Arvinas
Manufacturing · Connecticut, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
5 Science Park 395, New Haven, Connectic...Phone Number
(203) 535-1456Website
www.arvinas.comRevenue
$262.6 MillionStock Symbol
ARVNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About Arvinas
Founded in 2013, Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company's headquarters in New Haven, Connecticut.Explore more
Arvinas Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arvinas your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Arvinas recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Arvinas launches new products
Click to see if Arvinas had a recent Job posting/layoffs
Arvinas, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Arvinas is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Arvinas
Website visits: Recent activity has been detected on your website
Check if Arvinas has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Arvinas has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Arvinas
Compare insights from companies similar to Arvinas, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Arvinas is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Arvinas is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Arvinas.
Arvinas financials insights
Gather financial insights about Arvinas, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$15M
Corporate Investment
$3.3M
2015
Series B
$41.6M
2018
Series C
$55M
Stock Offering
$120M
Arvinas Tech Stack
A closer look at the technologies used by Arvinas
See more technologies
Most Recent Scoops
Project
Arvinas is advancing ARV-027, an oral PROTAC degrader specifically designed to eliminate the toxic polyglutamine expanded androgen receptor (polyQ AR) from muscle cells, targeting Spinal and Bulbar Muscular Atrophy (SBMA) a progressive neuromuscular disorder with no approved disease-modifying therapies with the first 3 cohorts of a Phase I single ascending dose study in healthy volunteers enrolled.
Project
Arvinas is advancing ARV-806, a PROTAC designed to potently and selectively eliminate both on and off forms of KRAS G12D, with preclinical results demonstrating approximately 25 to 40-fold greater potency than clinical-stage KRAS G12D inhibitors and degraders and durable degradation greater than 90% for 7 days after a single dose.
Clinical Operations
Project
Arvinas has announced the FDA approval of VEPPANU (vepdegestrant) for the treatment of ESR1-mutant, ER-positive, HER2-negative advanced breast cancer, as minimal second-line treatment options have previously existed for these patients.
Pain Point
Arvinas has announced that its planned Phase I-B clinical trial with Progressive Supranuclear Palsy (PSP) in the US is on clinical hold, as the FDA requested final data from chronic toxicology studies in non-human primates following the 30-day IND review period a request that goes beyond what was originally outlined by the FDA in a prior meeting with no US patients treated to date and trial initiation not anticipated until the end of 2026, when the required data are expected to be available in mid-2026; plans for trials in the EU are not impacted, and there is no change to guidance on the start of the planned global Phase II study.
Clinical Operations
Project
Arvinas News & Media
Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.Arvinas Employees Give Back During Company-wide Impact Day
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company’s fourth Arvinas Impact Day this past Friday. This company-wide day of service brings employees together to give back to their communities through volunteer activities thatArvinas Q1 Earnings Call Highlights
Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation. President and Chief Executive Officer Randy Teel said the appArvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline –
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Arvinas
Sign Up For FreeTo access detailed company insights
Founded in 2013, Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company's headquarters in New Haven, Connecticut.... Read More
